Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Edge, PPO MultiPlan Sign Deal Covering Bladder Cancer Dx

NEW YORK (GenomeWeb) – Pacific Edge recently announced a contract with preferred provider organization MultiPlan covering Pacific Edge's Cxbladder test.

The deal provides coverage of the bladder cancer test to MultiPlan's members and includes Pacific Edge's participation in the MultiPlan, PHCS, and PHCS Savility Networks. About 900,000 providers participate in MultiPlan's networks and about 68 million patients have access to the networks, Pacific Edge said.

The Cxbladder test is urine-based and comprises five biomarkers. It identifies patients with changes in gene expression and helps rule out cancer in patients with normal gene expression. The test is run out of the company's wholly owned subsidiary Pacific Edge Diagnostics' CAP-accredited laboratory in Hershey, Pa.

Earlier this year, Pacific Edge received NZ$4.5 million (US$3.8 million) from New Zealand crown entity Callaghan Innovation to accelerate the firm's development of molecular cancer detection technology.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.